Explores current and emerging applications of microbes as cancer-fighting agents
WILEY SERIES IN BIOTECHNOLOGY AND BIOENGINEERING
Anurag S. Rathore, Series Editor
Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. In recent years, researchers have been working on a new strategy: developing microbes and microbial products that specifically attack cancer cells.
This book breaks new ground in emerging cancer treatment modalities by presenting recent advances in the use of microorganisms and viruses as well as their products in cancer therapy. Seventeen chapters review the application of live microorganisms, high and low molecular weight products derived from microorganisms, and microbial products fused to cancertargeting molecules. In addition, the book highlights the benefits of a multi-target approach
to destroy cancer cells. Readers will not only discover the results and significance of basic and clinical research, but also encouraging results from clinical trials.
Emerging Cancer Therapy is divided into three sections:
* Section 1: Live/Attenuated Bacteria and Viruses as Anticancer Agents
* Section 2: Bacterial Products as Anticancer Agents
* Section 3: Patents on Bacteria/Bacterial Products as Anticancer Agents
With chapters written by leading pioneers in microbial, biotech, and cancer research, Emerging Cancer Therapy is recommended for biotechnologists, microbiologists, clinical oncologists, medicinal chemists, and biochemists. Readers will not only learn the tremendous potential of microbial and biotechnological approaches to cancer therapy, but also discover new directions of research for effective drug discovery and development.
Table des matières
Preface ix
Contributors xi
Part I Live/Attenuated Bacteria and Viruses as Anticancer Agents 1
1 Salmonella Typhimurium Mutants Selected to Grow Only in Tumors to Eradicate Them in Nude Mouse Models 3
Robert M. Hoffman
2 The Use of Living Listeria Monocytogenes as an Active Immunotherapy for the Treatment of Cancer 13
John Rothman, Anu Wallecha, Paulo Cesar Maciag, Sandra Rivera, Vafa Shahabi, and Yvonne Paterson
3 Bacillus Calmette-Guerin (BCG) for Urothelial Carcinoma of the Bladder 49
Timothy P. Kresowik and Thomas S. Griffith
4 Live Clostridia: A Powerful Tool in Tumor Biotherapy 71
Lieve Van Mellaert, Ming Q Wei, and Jozef Anné
5 Bifi dobacterium as a Delivery System of Functional Genes for Cancer Gene Therapy 99
Geng-Feng Fu, Yan Yin, Bi Hu, and Gen-Xing Xu
6 Replication-Selective Viruses for the Treatment of Cancer 119
Padma Sampath and Steve H. Thorne
7 Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy 141
Jason S. Buhrman, Tooba A. Cheema, and Giulia Fulci
Part II Bacterial Products as Anticancer Agents 179
8 Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design 181
Arsénio M. Fialho and Ananda M. Chakrabarty
9 Arginine Deiminase and Cancer Therapy 199
Lynn Feun, M. Tien Kuo, Ming You, Chung Jing Wu, Medhi Wangpaichitr, and Niramol Savaraj
10 Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy 219
Sergey A. Kaliberov and Donald J. Buchsbaum
11 Bacterial Proteins against Metastasis 243
Anna Maria Elisabeth Walenkamp
12 Pseudomonas Exotoxin A-Based Immunotoxins for Targeted Cancer Therapy 269
Philipp Wolf and Ursula Elsässer-Beile
13 Denileukin Diftitox in Novel Cancer Therapy 289
Lin-Chi Chen and Nam H. Dang
14 The Application of Cationic Antimicrobial Peptides in Cancer Treatment: Laboratory Investigations and Clinical Potential 309
Ashley L. Hilchie and David W. Hoskin
15 Prodiginines and Their Potential Utility as Proapoptotic Anticancer Agents 333
Neil R. Williamson, Suresh Chawrai, Finian J. Leeper, and George P.C. Salmond
16 Farnesyltransferase Inhibitors of Microbial Origins in Cancer Therapy 367
Jingxuan Pan and Sai-Ching Jim Yeung
17 The Use of RNA and Cp G DNA as Nucleic Acid-Based Therapeutics 379
Jörg Vollmer
Part III Patents On Bacteria/Bacterial Products as Anticancer Agents 403
18 The Role and Importance of Intellectual Property Generation and Protection in Drug Development 405
Arsénio M. Fialho and Ananda M. Chakrabarty
Index 421
A propos de l’auteur
ARSÉNIO FIALHO, PHD, is Associate Professor in the Department of Chemical and Biological Engineering and Principal Investigator for the Institute of Biotechnology and Bioengineering in the Instituto Superior Técnico at the Universidade Técnica de Lisboa, Portugal. His current scientific interests are focused on the study of bacterial proteins, such as azurin and Laz, as novel multi-targeted drug candidates with anticancer activities. He is the author or coauthor of more than fifty papers in peer-reviewed scientific journals and, during the last four years, became the holder of five U.S. patents. Dr. Fialho teaches courses in biochemistry, molecular biology, and bioinformatics.
ANANDA CHAKRABARTY, PHD, is Distinguished University Professor in the Department of Microbiology and Immunology at the University of Illinois College of Medicine at Chicago. In addition to more than 250 research publications, he has secured nine U.S. patents during the last four years on azurin and Laz, two bacterial proteins with anticancer, anti-viral and anti-parasitic activities. He also is the recipient of a patent on the first life form, a genetically manipulated pseudomonad designed to degrade multiple hydrocarbons present in crude oil, as decided by the U.S. Supreme Court in 1980 in the celebrated court case Diamond v. Chakrabarty.
Plus d’ebooks du même auteur(s) / Éditeur
27 930 Ebooks dans cette catégorie
